Former CFO of BlackRock Capital Investment Corporation and AIG Capital Partners' Global Emerging Markets Group Corinne Pankov...
July 21 2020 - 8:00AM
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (“Aditxt” or the
“Company”) (NASDAQ: ADTX), a life sciences company developing
technologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
announced that it has appointed Corinne Pankovcin as Chief
Financial Officer, effective as of July 2, 2020.
“Corinne Pankovcin is a skilled financial
executive with 30 years of public company financial experience. Her
reputation for building strong relationships with key stakeholders,
combined with her in depth knowledge of the requirements of SEC
regulated public companies, will be of great benefit to Aditxt as
we continue to grow the company and execute on our strategic plans.
We welcome Corinne to the Aditxt team and look forward to her
contributions to our growth,” said Amro Albanna, Co-founder and
Chief Executive Officer of Aditxt.
Prior to joining Aditxt, Ms. Pankovcin was the
Chief Financial Officer and Managing Director of Business
Development Corporation of America (“BDCA”), a business development
company, from December 2015 to July 2019. At BDCA, Ms. Pankovcin
was responsible for strategic planning, financial forecasting, and
financial reporting, in addition to being a trusted advisor and
resource to BDCA leadership. From January 2011 to August
2015, Ms. Pankovcin was the Chief Financial Officer and Treasurer
of BlackRock Capital Investment Corporation, and a Managing
Director of Finance at BlackRock Investment Management LLC. Prior
to joining BlackRock, Ms. Pankovcin was a senior member of Finance
& Accounting of Alternative Investments and served as Chief
Financial Officer for the Global Emerging Markets products group at
AIG Capital Partners. Ms. Pankovcin began her career with
PricewaterhouseCoopers LLP, where she ultimately held the role of
Senior Manager of Business Assurance for Consumer Products,
Manufacturing, and Middle Market industries from 1991 to 2001.
Ms. Pankovcin earned a Bachelor of Science
degree in Accounting from Dowling College and a Master of Business
Administration from Hofstra University. She is a Certified Public
Accountant.
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Words such as “may,” “might,” “will,”
“should,” “believe,” “expect,” “anticipate,” “estimate,”
“forecast,” “project,” “plan,” “intend” or similar expressions, or
statements regarding intent, belief, or current expectations,
including the Company’s expectations regarding the proposed
offering of the Company’s shares of common stock, including as to
the consummation of the offering described above and the size of
the offering are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company’s filings with the Securities and Exchange
Commission, including, but not limited to, risk factors relating to
its business contained therein. Thus, actual results could be
materially different. The Company expressly disclaims any
obligation to update or alter statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Relations Contact:
PCG Advisory: Jeff RamsonChief Executive
OfficerIR@aditxt.com 646-762-4518www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024